LB Pharmaceuticals Inc LBRX
45.12 USD +3.11 (+7.40%)
At closeNov 9, 2026, 4:00 PM EST
45.12 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
41.54 Day range 45.77
14.32 52-week range 50.16
- YTD
- +102.70%
- 1 year
- +193.94%
- Market cap
- 1.46B
- EPS (ttm)
- -1.12
- Shares out
- 32.36M
- Forward P/E
- -7.99
- YTD return
- +102.70%
- 1-year return
- +193.94%
- Volume
- 472.30K
- Avg volume
- 359.26K
- Open
- 43.05
- Previous close
- 42.01
- Day's range
- 41.54 – 45.77
- 52-week range
- 14.32 – 50.16
- Analysts
- Strong Buy
- Price target
- 58.00 (+28.5%)
- Earnings date
- Mar 25, 2027
No chart data for this range yet.
Key statistics
- Enterprise value
- 960.97M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -110.52M
- Total cash
- 403.76M
- Total debt
- 5.16M
- Return on equity
- -38.80%
- Short % of float
- 20.29%
- 50-day average
- 40.57
- 200-day average
- 33.04
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.00 +28.5% upside
Now 45.12
- Target (low)
- 35.00
- Target (mean)
- 58.00
- Target (high)
- 80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -1.85.
Financials — quick view
LBRX Revenue — quarterly 0
LBRX Net income — quarterly -59.07M
LBRX EPS — quarterly -1.79
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Dec 30, 2026 | -1.64 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.62 | -1.79 | -0.17 | -10.49% |
| Aug 11, 2026 | Jun 30, 2026 | -0.80366 | -1.71 | -0.91 | -112.78% |
| May 12, 2026 | Mar 31, 2026 | -0.75 | -0.67 | +0.08 | +10.67% |
| Mar 26, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.61 | -0.04 | -7.02% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | init | — | Buy |
| Oct 6, 2026 | Guggenheim | init | — | Buy |
| Oct 5, 2026 | Roth Capital | down | Buy | Neutral |
| Oct 2, 2026 | Needham | init | — | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | BMO Capital | main | Outperform | Outperform |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lbpharma.us
News
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday 
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65 
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80 - Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
LB Pharmaceuticals Appoints Joseph Miller CFO 
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday 
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60 - BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
Your note
Sign in to keep a note on LBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| NUSSBAUM RAN | Director | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 10.39% | 3,352,804 | 151.28M | Jun 29, 2026 |
| Blackrock Inc. | 8.48% | 2,734,305 | 123.37M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.85% | 2,208,604 | 99.65M | Jun 29, 2026 |
| Trails Edge Capital Partners, LP | 4.72% | 1,523,022 | 68.72M | Jun 29, 2026 |
| Commodore Capital Lp | 4.65% | 1,500,000 | 67.68M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 4.64% | 1,497,293 | 67.56M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 2.15% | 692,905 | 31.26M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.08% | 672,000 | 30.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.80% | 581,677 | 26.25M | Sep 29, 2026 |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 1.76% | 567,627 | 25.61M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.86% | 278,887 | 12.58M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.76% | 245,436 | 11.07M | Aug 30, 2026 |